BLRD Research Career Scientist Award Application

此申请表是为Niketa A.Patel，Ph.D.，Active的8/8 VA，PI颁发的研究职业科学家奖 VAMR奖，2005年以来的国家同行评议研究支助，办公室(303-4室)和 詹姆斯·A·黑利退伍军人医院研究服务空间的实验室(300号和303号套房)。我有过 在代谢的细胞和分子机制方面开发并建立了一个强大的程序 疾病。我的研究整合了人类研究(翻译与人类的相关性 生理学/病理生理学)、体外细胞研究(用于选择性剪接的机制研究和 非编码RNA的作用；因果关系的阐明)，活体啮齿动物研究(用于确定整体 新型抑制剂和稳定剂对人体系统的影响)和尖端转录物(如 编码和非编码RNA和细胞信号的全球分析)。我已经成功地 在将RNA生物学与生物相关系统中的信号相结合方面开拓了利基市场 理解它如何可能是疾病的原因或结果。总体而言，我的项目重点是 脂肪作为内分泌器官的作用及其分泌体对机体代谢过程的影响 尸体。我的研究对证明肥胖时脂肪干细胞的生态位发生了变化起到了关键作用。 61-83%的国防部受益者和78%的退伍军人事务部受益者超重或肥胖，这是一个显著的 高于一般人群的百分比(退伍军人事务部/国防部临床指南，2014)。超过9.2 每年因肥胖及其相关疾病而付出的代价超过17亿美元 而美国的总支出已经上升到每年2540亿美元。My的一个重要应用 人类脂肪干细胞来源的外切体作为治疗手段的研究进展 治疗创伤性脑损伤(TBI)相关后遗症。颅脑损伤显著影响退伍军人的生活质量 以及我们国家的军事准备。明显更高的美国士兵和退伍军人比例(22%) 在伊拉克和阿富汗服役(OEF/OIF)的人与来自越南的人相比有脑损伤 Era(12%)。退伍军人事务部预计，TBI的10年(2016-2025年)经济成本为22亿美元， 为OEF/OIF退伍军人提供5亿美元(CRS关于TBI的报告，2015)。来自人类脂肪的外切体- 来源干细胞为治疗慢性肾功能衰竭提供了一种新的、无细胞再生的方法 TBI。我的实验室最近的出版物(斯帕克斯等人，2019年生物化学杂志；史等人，细胞 化学生物学，2019；Patel等人，神经炎症杂志2018)展示了广泛的工作 凭借尖端技术和新疗法的发展，在全国范围内 和国际认可。这些出版物遵循了我职业生涯中翻译出版的趋势 在影响力较大的期刊上进行相关性强、机械性强的研究。我在退伍军人管理局拥有五项USPTO专利 主张权利，这是我作为一名科学家退伍军人管理局职责的一部分。我被邀请了 在国家和国际科学会议上发言。我在当地退伍军人事务部服务，在IACUC服务， 自2007年起担任SRS和研发委员会成员，并担任JAHVH分子核心设施主任。在SRS，我 曾担任副主席(2012-14年)和主席(2015-2019年)。我在退伍军人管理局任职于国家级 职业发展审查委员会、退伍军人事务部功勋审查委员会和NIH CADO 委员会。在我的南佛罗里达附属大学，我在研究生和医学课程中任教 从2002年开始。我曾指导过本科生、研究生和医学生 事业成功。多年来，我与退伍军人事务部和非退伍军人事务部、临床医生和科学家进行了合作 这导致了出版物和国家赠款的出现。总的来说，我在以下方面做出了重大贡献 JAHVH的研究使命是进行尖端的翻译研究，以促进 并为VAMC的长期研究目标做出贡献。

This application is for Research Career Scientist award for Niketa A. Patel, Ph.D., 8/8th VA, PI of active VAMR award, national peer-reviewed research support since 2005, office (Room 303-4) and laboratory (Suites 300 and 303) in James A. Haley Veterans’ Hospital Research Service space. I have developed and established a strong program in cellular and molecular mechanisms of metabolic diseases. My research integrates human studies (translational relevance to human physiology/pathophysiology), in vitro cell studies (for mechanistic studies of alternative splicing and role of noncoding RNA; elucidation of cause vs. effect), in vivo rodent studies (for determining whole body systemic impact of novel inhibitors and stabilizers) and cutting-edge transcriptomics (such as RNAseq global analysis of coding and noncoding RNA and cellular signaling). I have successfully carved a niche in integrating RNA biology with signaling in biologically relevant systems and understanding how it may be a cause or consequence of a disease. Overall, my projects focus on the role of adipose as an endocrine organ and impact of its secretome on the metabolic processes in the body. My research was pivotal to demonstrate that the adipose stem cells’ niche is altered in obesity. 61-83% of DoD beneficiaries and 78% of VA beneficiaries are over-weight or obese, a significantly higher percent compared to general population (VA/DoD Clinical guideline, 2014). With over 9.2 million beneficiaries, the cost of obesity and its related diseases exceeds $1.7 billion annually for the VA while total US expenditures has risen to $254 billion annually. An important application of my research is development of exosomes derived from human adipose stem cells as treatment for traumatic brain injury (TBI) related sequelae. TBI significantly affects the quality of life of veterans and military readiness of our country. A significantly higher percent (22%) of US soldiers and veterans who served in Iraq and Afghanistan (OEF/OIF) have brain injuries compared to those from Vietnam era (12%). The VA projects the 10-year (2016–2025) economic costs of TBI to be $2.2 billion with $0.5 billion for OEF/OIF veterans (CRS report on TBI, 2015). The exosomes from human adipose- derived stem cells provide a novel, cell-free regenerative approach for treatment of chronic effects of TBI. My lab’s recent publications (Sparks et al, Journal of Biological Chemistry 2019; Shi et al, Cell Chemical Biology, 2019; Patel et al, Journal of Neuroinflammation 2018) showcasing extensive work with cutting edge technologies and development of new therapeutics has received immense national and international recognition. These publications follow my career’s trend of publishing translationally relevant, mechanistically strong research in high-impact journals. I hold five USPTO patents with VA asserted rights which were developed as part of my VA duties as a scientist. I have been an invited speaker at national and international scientific meetings. I serve my local VA by serving on IACUC, SRS and R&D committees since 2007 and as Director of JAHVH molecular core facility. At SRS, I have served as vice-chair (2012-14) and Chair (2015-2019). I serve at the national level in the VA Career Development review committee, VA ENDA Merit review Committee and NIH CADO committees. At my affiliate University of South Florida, I teach in the graduate and medical courses since 2002. I have mentored undergraduate, graduate and medical students who have established successful careers. Over the years, I have collaborated with VA and non-VA, clinicians and scientists which has resulted in publications and national grants. Overall, I have contributed significantly to JAHVH research mission of conducting cutting-edge translational research to boost healthcare of Veterans and contributing to the long-term research goals of VAMC.